On November 1, our team of Nephrology Region Business Directors joined Reata. Their first task is to build our sales organization, identifying experienced kidney and rare disease sales professionals to join our team early next year. Now with Friedreich's ataxia back in focus, we're advancing similar commercial work to prepare us for the launch of omaveloxolone in neurology. For both therapeutic areas, disease awareness efforts will continue through approval and launch, highlighting the significant unmet need, the urgency to treat and the severity of these life-threatening diseases.